Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study.

Front Immunol · 2025 · PMC12197949 · PMID 40574843

Europe PMC DOI

hedged sentence

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

did not reach statistical significanceP =0.096so close (0.05 < p ≤ 0.1)

The median OS was 16.2 months in the TACE+LEN group and 21.0 months in the TACE+LEN+PD-1 group, representing a numerical extension of 4.8 months, though this difference did not reach statistical significance (HR=1.510, 95% CI 0.929-2.453, P =0.096) ( Figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.